Vemurafenib Treatment of Pleomorphic Xanthoastrocytoma in a Child With Down Syndrome.
BRAF V600E mutation
brain tumor
down syndrome
pleomorphic xanthoastrocytoma
vemurafenib
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
11
2018
accepted:
26
03
2019
entrez:
30
4
2019
pubmed:
30
4
2019
medline:
30
4
2019
Statut:
epublish
Résumé
Brain tumors are the most common solid neoplasms of childhood, but they are very rarely reported in children with Down Syndrome (DS), who develop more commonly different types of malignancies. In particular, we hereby report the case of an 8-years-old child with DS that presented to our attention for neurological and endocrinological issues. Brain imaging revealed the presence of a mass that was partially resected revealing a histological diagnosis of Pleomorphic Xanthoastrocytoma (PXA), a rare WHO grade II tumor extending from the diencephalic region into the surrounding brain tissue. These tumors can harbor the
Identifiants
pubmed: 31032231
doi: 10.3389/fonc.2019.00277
pmc: PMC6474392
doi:
Types de publication
Case Reports
Langues
eng
Pagination
277Références
Lancet. 2000 Jan 15;355(9199):165-9
pubmed: 10675114
Genome Biol. 2000;1(2):REVIEWS0002
pubmed: 11178230
Neuro Oncol. 2001 Jul;3(3):152-8
pubmed: 11465395
Int J Cancer. 2001 Sep 1;93(5):741-4
pubmed: 11477589
Arch Dis Child. 2001 Oct;85(4):321-5
pubmed: 11567943
Nat Genet. 2002 Sep;32(1):148-52
pubmed: 12172547
Arch Intern Med. 2003 Mar 24;163(6):705-11
pubmed: 12639204
J Urol. 2004 Mar;171(3):1250-3
pubmed: 14767322
J Surg Res. 2004 Feb;116(2):337-49
pubmed: 15013374
Arch Dis Child. 2004 Nov;89(11):1014-7
pubmed: 15499053
Int J Cancer. 2006 Apr 1;118(7):1769-72
pubmed: 16231334
Physiol Res. 2006;55(3):233-44
pubmed: 16238454
Br J Cancer. 2006 May 8;94(9):1221-5
pubmed: 16570048
J Pediatr. 2006 Aug;149(2):233-6
pubmed: 16887441
Am J Med Genet C Semin Med Genet. 2006 Aug 15;142C(3):196-205
pubmed: 17048356
J Intellect Disabil Res. 2007 Mar;51(Pt 3):228-31
pubmed: 17300418
J Pediatr. 2008 Jan;152(1):15-9
pubmed: 18154890
J Clin Invest. 2008 May;118(5):1739-49
pubmed: 18398503
Biochim Biophys Acta. 2009 Apr;1792(4):353-63
pubmed: 19419698
Pediatr Int. 2011 Feb;53(1):72-7
pubmed: 20573041
Acta Neuropathol. 2011 Mar;121(3):397-405
pubmed: 21274720
PLoS One. 2011 Mar 29;6(3):e17948
pubmed: 21479234
Clin Cancer Res. 2011 Dec 15;17(24):7595-604
pubmed: 22038996
Eur J Pediatr. 2012 Sep;171(9):1301-7
pubmed: 22113227
ISRN Oncol. 2012;2012:982769
pubmed: 23213569
J Neurooncol. 2013 Mar;112(1):107-14
pubmed: 23307327
AJNR Am J Neuroradiol. 2014 Nov-Dec;35(11):2192-6
pubmed: 24994821
J Clin Oncol. 2016 Apr 1;34(10):e87-9
pubmed: 25092772
Brain Pathol. 2015 Sep;25(5):575-86
pubmed: 25318587
Pediatr Blood Cancer. 2015 Apr;62(4):724-7
pubmed: 25382612
Eur J Immunol. 2015 Mar;45(3):903-14
pubmed: 25472482
World Neurosurg. 2015 Sep;84(3):866.e1-6
pubmed: 25862935
J Biomed Sci. 2015 Jun 11;22:41
pubmed: 26062604
Int J Clin Exp Med. 2015 Nov 15;8(11):19840-9
pubmed: 26884894
J Pediatr Hematol Oncol. 2016 May;38(4):283-7
pubmed: 26907658
Genet Med. 2016 May;18(5):459-66
pubmed: 27126496
Childs Nerv Syst. 2016 Dec;32(12):2439-2446
pubmed: 27444290
Neuro Oncol. 2017 May 1;19(5):726-735
pubmed: 28039365
Cold Spring Harb Mol Case Stud. 2017 Mar;3(2):a001396
pubmed: 28299358
N Engl J Med. 1966 Jul 14;275(2):87-93
pubmed: 5327812